Alpha Teknova, Inc. (TKNO): Cost of Revenue
$27.08M
Year ended 2025-12-31
$28.58M
Trailing 12 months to 2026-06-30
+4.2%
3-year compound annual growth
+14.9%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $27.08M | -11.3% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $30.51M | +15.6% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $26.39M | +10.2% | 2025-03-07, From 2023-01-01 |
| 2022-12-31 | $23.94M | +24.2% | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | $19.27M | +42.3% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $13.54M | n/a | 2022-03-18, From 2020-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $27.08M | -11.3% |
| Immucell Corp (ICCC) | 2025-12-31 | $16.20M | -12.7% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $3.30M | -10.9% |
| Anbio Biotechnology (NNNN) | 2025-12-31 | $1.10M | -52.0% |
| Biomerica Inc (BMRA) | 2026-05-31 | $4.09M | -15.0% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $1.75M | +66.2% |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | $247.90M | -1.7% |
| Neogen Corp (NEOG) | 2026-05-31 | $461.90M | -2.4% |
| Celldex Therapeutics, Inc. (CLDX) | 2025-12-31 | $200.0K | 0.0% |
Compare TKNO, ICCC, AWHL, NNNN side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗